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We read with interest the article “Henoch-Schönlein 
Purpura in adults” by López Meiller et al.1 They reported 
3 adult patients with Henoch-Schönlein nephritis (HSN)
(one with hematuria and two with heavy proteinuria) who 
were treated with IV cyclophosphamide (1g/m²/month for 
six months).1
Although the treatments of severe Henoch-Schönlein 
nephritis still remains controversial, oral cyclophosphamide 
has been used in children with severe Henoch-Schönlein 
nephritis with conflicting results.2-4 Tanaka et al. reported 
that prompt initiation of oral prednisolone (1.5 mg/
kg/day) combined with an 8-week course of oral 
cyclophosphamide (2 mg/kg/day) therapy could be effective 
not only in regressing the renal histologic findings but 
also in decreasing proteinuria in children with severe 
Henoch-Schönlein nephritis.2 Kawasaki et al. also showed 
that methylprednisolone and urokinase pulse therapy 
combined with oral cyclophosphamide was more useful 
for children with severe Henoch-Schönlein nephritis than 
methylprednisolone and urokinase pulse therapy alone.3 
However, when Tarshish et al. performed a randomized 
controlled study (supportive therapy with or without oral 
cyclophosphamide 90 mg/m2/day for 42 days), there were no 
differences in outcome between the two groups.4
Nevertheless, there has been no study on the therapeutic 
effect of intravenous cyclophosphamide therapy on children 
or adults with severe Henoch-Schönlein nephritis. On 
this point, López Meiller et al.’s study1 is novel and has 
important clinical implications for the treatment of severe 
Henoch-Schönlein nephritis. However, the indications and 
duration of intravenous cyclophosphamide therapy should 
also be considered, because this protocol (intravenous 
cyclophosphamide, 1g/m²/month for six months) which has 
been previously used in severe diffuse proliferative lupus 
nephritis can cause various side effects.5 Therefore, at least 
heavy proteinuria or severe histologic findings should be 
the indications for intravenous cyclophosphamide therapy 
in severe Henoch-Schönlein nephritis. However it should 
be noted that one patient in the López Meiller et al.’s study1 
who showed hematuria without proteinuria was treated with 
intravenous cyclophosphamide. Also, one or two pulses 
of IV cyclophosphamide might be enough to control renal 
inflammations in Henoch-Schönlein nephritis, because two 
Henoch-Schönlein purpura patients with heavy proteinuria 
treated with 6 pulses of IV cyclophosphamide had shown a 
favorable clinical response after only one pulse.1
Therefore, further studies should be performed to evaluate 
the therapeutic effect of IV or oral cyclophosphamide in a 
large number of adults with severe Henoch-Schönlein 
nephritis, and the dose and duration of therapy should also 
be elucidated in the future.
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